Arleigh McCurdy
Overview
Explore the profile of Arleigh McCurdy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long B, McCurdy A, Koyfman A, Rosenberg H
Am J Emerg Med
. 2024 Dec;
88:172-179.
PMID: 39643958
Introduction: Multiple myeloma (MM) and its complications carry a high rate of morbidity and mortality. Objective: This review evaluates MM and its complications, including presentation, diagnosis, and management in the...
2.
Tanguay M, Roy J, Su J, Gul E, Reece D, Venner C, et al.
Cancer Med
. 2024 Nov;
13(21):e70332.
PMID: 39499045
Background: Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods: We explored disease characteristics, treatments, and...
3.
Ebraheem M, Chakraborty R, Rochwerg B, Visram A, Mohyuddin G, Venner C, et al.
Blood Adv
. 2024 Sep;
8(23):5993-6002.
PMID: 39348665
Quadruplet regimens (anti-CD38 monoclonal antibodies [mAbs] with proteasome inhibitor [PI] and immunomodulatory drugs [IMiDs]) are increasingly being investigated in newly diagnosed multiple myeloma (NDMM). The objective of our study was...
4.
McCurdy A, Reece D, Louzada M, White D, Parkin S, Chu M, et al.
Blood Cancer J
. 2024 Sep;
14(1):155.
PMID: 39261451
Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38 mAbs after first- or second-line...
5.
Visram A, Chan K, Seow H, Pond G, Gayowsky A, Mohyuddin G, et al.
Haematologica
. 2024 Sep;
110(1):228-233.
PMID: 39219457
No abstract available.
6.
Garderet L, Gras L, Koster L, Baaij L, Hamad N, DSouza A, et al.
Am J Hematol
. 2024 Aug;
99(11):2084-2095.
PMID: 39158218
Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected data on baseline characteristics and...
7.
Meraz-Munoz A, Mian H, Kirkwood D, Jeyakumar N, McCurdy A, Tangri N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Aug;
24(11):e861-e869.
PMID: 39117532
Background: Pomalidomide-based regimens are the cornerstone of treatment for relapsed/refractory MM (RRMM). Despite the high incidence of chronic kidney disease (CKD) in RRMM, individuals with advanced CKD have been excluded...
8.
Venner C, Duggan P, Song K, Reece D, Sharma S, Su J, et al.
Transplant Cell Ther
. 2024 Jul;
30(9):889-901.
PMID: 38971462
In patients with multiple myeloma (MM), the presence of high-risk cytogenetic abnormalities is associated with worse disease control and survival. Autologous stem cell transplant (ASCT) does benefit these patients. Tandem...
9.
Kaedbey R, Reece D, Venner C, McCurdy A, Su J, Chu M, et al.
EJHaem
. 2024 Jun;
5(3):474-484.
PMID: 38895063
Multiple myeloma remains an incurable cancer mostly affecting older adults and is characterized by a series of remission inductions and relapses. This study aims to evaluate the outcomes in newly...
10.
Mian H, Seow H, Balitsky A, Cheung M, Gayowsky A, Tay J, et al.
Oncologist
. 2024 Apr;
29(6):519-526.
PMID: 38636951
Developing prognostic tools specifically for patients themselves represents an important step in empowering patients to engage in shared decision-making. Incorporating patient-reported outcomes may improve the accuracy of these prognostic tools....